Special Issue

Role of Inflammasomes in Health and Diseases

Message from the Guest Editor

Inflammasomes are a topic of growing interest today, as they are biologic entities transversely implicated in the pathogenesis of many acute and chronic inflammationrelated diseases. The constitution and cleavage actions of such multi-protein complexes underlie the functioning of the innate response to various inflammatory stimuli. The final result is a particular form of programmed cell death, namely, pyroptosis. In the absence of relevant disorders, inflammasomes such as NLRP3, NAIP/NLRC4, and others act as intracellular 'sensors' of exogenous or endogenous aggressions via PAMPs and DAMPs. For this reason, targeted therapies that may interfere with inflammasome signaling deserve to be thoroughly developed. This Special Issue aims to bring together the main scientific proposals on the subject, covering everything from normal pathophysiology to the most recent clinical and translational findings in inflammatory diseases.

Guest Editor

Dr. Alessandro Lucchesi

Hematology Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy

Deadline for manuscript submissions

closed (30 June 2023)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/124523

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).